Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel prognostic six-CpG signature in glioblastomas.

CNS neuroscience & therapeutics - 1 Mar 2018

Yin An-An, Lu Nan, Etcheverry Amandine, Aubry Marc, Barnholtz-Sloan Jill, Zhang Lu-Hua, Mosser Jean, Zhang Wei, Zhang Xiang, Liu Yu-He, He Ya-Long

Abstract excerpt

AIMS: We aimed to identify a clinically useful biomarker using DNA methylation-based information to optimize individual treatment of patients with glioblastoma (GBM). METHODS: A six-CpG panel was identified by incorporating genome-wide DNA methylation data and clinical information of three distinct discovery sets and was combined using a risk-score model. Different validation sets of GBMs and lower-grade gliomas...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Brain

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain Neoplasms

Share to CpG Islands

Share to DNA Methylation

Share to Follow-Up Studies

Share to Glioblastoma

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 29350455
DOI: 10.1111/cns.12786
PMCID: PMC6489960

Genes

MGMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A novel prognostic six-CpG signature in glioblastomas.PMID 29350455Read ↗

Potent predictive CpG signature for temozolomide response in non-glioma-CpG island methylator phenotype glioblastomas with methylated MGMT promoter.Semantic proximity Read ↗

Integrative analysis identifies an immune-relevant epigenetic signature for prognostication of non-G-CIMP glioblastomas.Semantic proximity Read ↗

Development and Validation of a Novel DNA Methylation-Driven Gene Based Molecular Classification and Predictive Model for Overall Survival and Immunotherapy Response in Patients With Glioblastoma: A Multiomic AnalysisSemantic proximity Read ↗

A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to TemozolomideSemantic proximity Read ↗

DNA methylation-based epigenetic signatures predict somatic genomic alterations in gliomasSemantic proximity Read ↗

Identification of intrinsic subtype-specific prognostic microRNAs in primary glioblastomaSemantic proximity Read ↗

A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.Semantic proximity Read ↗

A three-gene signature for prognosis in patients with MGMT promoter-methylated glioblastomaSemantic proximity Read ↗

Integrative Analysis of DNA Methylation and Gene Expression Identify a Three-Gene Signature for Predicting Prognosis in Lower-Grade GliomasSemantic proximity Read ↗

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.Semantic proximity Read ↗

MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.Semantic proximity Read ↗

Methylation subgroup and molecular heterogeneity is a hallmark of glioblastoma: implications for biopsy targeting, classification and therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.